Superselective transarterial chemoembolization for hepatocellular carcinoma: Recent progression and perspective

Oncology

Volumn 81, Issue SUPPL. 1, 2011, Pages 105-110

  Takayasu, Kenichi ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

BCLC staging system; Hepatocellular carcinoma; Japanese guidelines; Transcatheter arterial chemoembolization; Treatment algorithm

Indexed keywords

ALPHA FETOPROTEIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FIBROBLAST GROWTH FACTOR 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MICROSPHERE; MITOMYCIN C; SOMATOMEDIN; SORAFENIB; VASCULOTROPIN; YTTRIUM 90; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER;

ALOPECIA; CANCER INVASION; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHOLECYSTITIS; GASTROENTERITIS; HUMAN; JAPANESE; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER INJURY; MOLECULARLY TARGETED THERAPY; PANCREATITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIATION PNEUMONIA; REVIEW; SKIN DISCOLORATION; STOMACH ULCER; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DISEASE PROGRESSION; DOXORUBICIN; HUMANS; JAPAN; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 84855314695     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000333269     Document Type: Review

References (46)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. (Pubitemid 40372904)
2. El-Serag HB: Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127:S27-S34.
3. Fattovich G, Stroffolini T, Zagni I, Donato F: Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127:S35-S50. (Pubitemid 39423368)
4. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al.: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
5. Ikai I, Kudo M, Arii S, Omata M, Kojiro M, Sakamoto M, et al.: Report of the 18th follow-up survey of primary liver cancer in Japan. Hepatol Res 2010; 40: 1043-1059.
6. Kudo M: Current situation of HCC management in Japan. Abstracts.< The 2nd Asia-Pacific primary liver cancer expert meeting, Osaka, 2011, p 198.
7. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al.: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739. (Pubitemid 34607087)
8. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al.: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171. (Pubitemid 34454013)
9. Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-442. (Pubitemid 36152543)
10. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, et al.: Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: 6-25. (Pubitemid 44900485)
11. Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338.
12. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236. (Pubitemid 43112690)
13. Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, et al.: Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008; 38: 37-51. (Pubitemid 350182575)
14. Kudo M, Okanoue T: Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007; 72(suppl 1):2-15. (Pubitemid 350256660)
15. Takayama T: Hepatocellular carcinoma; in Clavien PA (ed): Malignant Liver Tumors: Current and Emerging Therapies, ed 3. London, Wiley-Blackwell, 2010, pp 317-323.
16. Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, Del Poggio P, et al.: Semi-annual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol 2010; 53: 291-297.
17. Uchida H, Ohishi H, Matsuo N, Nishimine K, Ohue S, Nishimura Y, et al.: Transcatheter hepatic segmental arterial embolization using lipiodol mixed with an anticancer drug and Gelfoam particles for hepatocellular carcinoma. Cardiovasc Intervent Radiol 1990; 13: 140-145. (Pubitemid 20269112)
18. Matsui O, Kadoya M, Yoshikawa J, Gabata T, Arai K, Demachi H, et al.: Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology 1993; 188: 79-83. (Pubitemid 23183103)
19. Takayasu K, Muramatsu Y, Maeda T, Iwata R, Furukawa H, Muramatsu Y, et al.: Targeted transarterial oily chemoembolization for small foci of hepatocellular carcinoma using a unified helical CT and angiography system: analysis of factors affecting local recurrence and survival rates. AJR Am J Roentgenol 2001; 176: 681-688. (Pubitemid 32181966)
20. Miyayama S, Matsui O, Yamashiro M, Ryu Y, Kaito K, Ozaki K, et al.: Ultraselective transcatheter arterial chemoembolization with a 2-F tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil. J Vasc Interv Radiol 2007; 18: 365-376. (Pubitemid 46616707)
21. Iwazawa J, Ohue S, Mitani T, Abe H, Hashimoto N, Hamuro M, et al.: Identifying feeding arteries during TACE of hepatic tumors: comparison of C-arm CT and digital subtraction angiography. AJR Am J Roentgenol 2009; 192: 1057-1063.
22. Okusaka T, Okada S, Nakanishi T, Fujiyama S, Kubo Y: Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma. Invest New Drugs 2004; 22: 169-176. (Pubitemid 38270472)
23. Terayama N, Matsui O, Gabata T, Kobayashi S, Sanada J, Ueda K, et al.: Accumulation of iodized oil within the nonneoplastic liver adjacent to hepatocellular carcinoma via the drainage routes of the tumor after transcatheter arterial embolization. Cardiovasc Intervent Radiol 2001; 24: 383-387. (Pubitemid 34081419)
24. Takayasu K, Arii S, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Kokudo N, Makuuchi M: Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol, in press.
25. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, et al.: Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8,510 patients. Gastroenterology 2006; 131: 461-469. (Pubitemid 44142456)
26. Lewandowski RJ, Mulcahy MF, Kulik LM, Riaz A, Ryu RK, Baker TB, et al.: Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology 2010; 255: 955-965.
27. Ueno K, Miyazono N, Inoue H, Nishida H, Kanetsuki I, Nakajo M: Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma: evaluation of three kinds of regimens and analysis of prognostic factors. Cancer 2000; 88: 1574-1581. (Pubitemid 30183142)
28. Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, et al.: Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011; 37: 212-220.
29. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al.: Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474-481. (Pubitemid 46201723)
30. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al.: Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52.
31. Malagari K, Pomoni M, Kelekis A, Pomoni A, Dourakis S, Spyridopoulos T, et al.: Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with Bead- Block for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010; 33: 541-551.
32. Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, et al.: Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008; 47: 71-81. (Pubitemid 351171043)
33. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al.: Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138: 52-64.
34. Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, et al.: Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011; 140: 497-507. e492.
35. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al.: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109. (Pubitemid 39331023)
36. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, et al.: BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006; 98: 326-334. (Pubitemid 43338212)
37. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al.: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
38. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al.: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
39. Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ, Cao GW: Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol 2008; 49: 523-529.
40. Li X, Feng GS, Zheng CS, Zhuo CK, Liu X: Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol 2004; 10: 2878-2882. (Pubitemid 39303010)
41. Virmani S, Rhee TK, Ryu RK, Sato KT, Lewandowski RJ, Mulcahy MF, et al.: Comparison of hypoxia-inducible factor-1alpha expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors. J Vasc Interv Radiol 2008; 19: 1483-1489.
42. Sun HC, Tang ZY: Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives. J Cancer Res Clin Oncol 2004; 130: 307-319.
43. Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, et al.: Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011; 47: 2117-2127.
44. Lencioni R, Zou J, Leberre M, Meinhardt G, Voliotis D, Bruix J, et al.: Sorafenib (SOR) or placebo (PL) in combination with transarterial chemoembolization (TACE) for intermediate- stage hepatocellular carcinoma (SPACE). Abstracts ASCO Meet, Chicago, 2010, p TPS178.
45. Chung Y, Kim B, Chen C, Wang J, Chu H, Yoon J, et al.: Study in Asia of the combination of transcatheter arterial chemoembolization (TACE) with sorafenib in patients with hepatocellular carcinoma (HCC) trial (START): second interim safety and efficacy analysis. Abstracts ASCO Meet, Chicago, 2010, p 4026.
46. Arai Y, Inaba Y, Yamamoto T, Kanai F, Aramaki T, Tanaka T, et al.: A randomized phase II study of TSU-68 in patients (pts) with hepatocellular carcinoma (HCC) treated by transarterial chemoembolization (TACE). Abstracts ASCO Meet, Chicago, 2010, p 4030.